United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $393.08.

UTHR has been the topic of a number of research reports. Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Morgan Stanley boosted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the transaction, the director now owns 1,750 shares in the company, valued at approximately $497,962.50. This represents a 69.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,000 shares of company stock valued at $23,110,950. 10.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. SVB Wealth LLC acquired a new position in shares of United Therapeutics in the first quarter valued at about $32,000. Dunhill Financial LLC grew its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics in the first quarter valued at about $49,000. Finally, Brooklyn Investment Group grew its stake in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 98 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of UTHR opened at $290.75 on Monday. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $417.82. The firm's 50 day moving average price is $300.99 and its two-hundred day moving average price is $327.34. The firm has a market cap of $13.12 billion, a P/E ratio of 11.60, a PEG ratio of 6.36 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the previous year, the firm posted $6.17 earnings per share. The business's revenue was up 17.2% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.